NCT04562831 - The NO-ALS Study: a Trial of Nicotinamide/pterostilbene Supplement in ALS. | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

October 7, 2020

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DIETARY_SUPPLEMENT

EH301 (Nicotinamide Riboside/Pterostilbene)

Comparison of 2 different dosages with placebo in newly diagnosed ALS patients and comparison of high dose with placebo in earlier ALS patients.

Trial Locations (9)

RECRUITING

Haukeland University Hospital, Bergen

RECRUITING

Vestre Viken HF, Drammen

RECRUITING

Helse Førde HF, Førde

RECRUITING

Helse Fonna HF, Haugesund

RECRUITING

Akershus University Hospital, Lørenskog

RECRUITING

Oslo University Hospital, Oslo

RECRUITING

Stavanger University Hospital, Stavanger

RECRUITING

Universitetssykehuset Nord-Norge, Tromsø

RECRUITING

St.Olavs Hospital HF, Trondheim